Journal of Antimicrobial Chemotherapy, Vol 39, 119-128, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
KA Cassady and RJ Whitley
The character of diseases caused by alphaherpesviruses has changed over the
last decade. The severity of disease and the frequency of acyclovir
resistance has increased with the increase in the number of
immunocompromised patients. Compounding the trend towards more virulent
herpes disease is the current emphasis towards outpatient management of
many diseases. Much of the current antiviral research focuses on providing
drugs with (i) improved oral bioavailability and pharmacokinetics which
permit less frequent oral or topical dosing for suppressive treatment of
herpes simplex virus (HSV) infections, (ii) different mechanisms of action
for synergic effects in treating resistant HSV infections in the
immunocompromised host and (iii) improved efficacy. Future antiviral agents
will probably target enzymes or viral factors essential for infection or
will inhibit other steps in the viral infection cycle, such as viral entry,
protein synthesis or capsid assembly. Medications that augment the immune
response constitute another pathway for combating herpes viral infections.
Many of the newer experimental agents target essential processes unique to
herpesvirus replication and, therefore, potentially have high selectivity.
REVIEW, TUTORIAL
New therapeutic approaches to the alphaherpesvirus infections
Ambulatory Care Center, The Children's Hospital of Alabama, Birmingham 35233, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H.-Y. Cheng, C.-M. Yang, T.-C. Lin, L.-T. Lin, L.-C. Chiang, and C.-C. Lin Excoecarianin, Isolated from Phyllanthus urinaria Linnea, Inhibits Herpes Simplex Virus Type 2 Infection through Inactivation of Viral Particles Evid. Based Complement. Altern. Med., October 6, 2009; (2009) nep157v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Cheng, T.-C. Lin, C.-M. Yang, K.-C. Wang, L.-T. Lin, and C.-C. Lin Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro J. Antimicrob. Chemother., April 1, 2004; 53(4): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chutkowski, B. Olson, A. McDonough, J. Mahoney, and J. J. McSharry Use of a Single Monoclonal Antibody To Determine the Susceptibilities of Herpes Simplex Virus Type 1 and Type 2 Clinical Isolates to Acyclovir Clin. Vaccine Immunol., November 1, 2002; 9(6): 1379 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. SIEGEL Diagnosis and management of recurrent herpes simplex infections J Am Dent Assoc, September 1, 2002; 133(9): 1245 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hayashi, K. Kawahara, C. Nakai, U. Sankawa, H. Seto, and T. Hayashi Evaluation of (1R,2R)-1-(5'-methylfur-3'-yl)propane-1,2,3-triol, a sphydrofuran derivative isolated from a Streptomyces species, as an anti-herpesvirus drug J. Antimicrob. Chemother., August 1, 2000; 46(2): 181 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jennings, T. L. Smith, F. Myhren, J. Phillips, and M. L. Sandvold Evaluation of a Novel, Anti-Herpes Simplex Virus Compound, Acyclovir Elaidate (P-4010), in the Female Guinea Pig Model of Genital Herpes Antimicrob. Agents Chemother., January 1, 1999; 43(1): 53 - 61. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. K. Patick and K. E. Potts Protease Inhibitors as Antiviral Agents Clin. Microbiol. Rev., October 1, 1998; 11(4): 614 - 627. [Abstract] [Full Text] [PDF]
|
|